The diagnostic and prognostic values of inflammatory markers in intraductal papillary mucinous neoplasm. Issue 10 (October 2021)

• Record Type: Journal Article
• Authors: Kim, Hongbeom; Jung, Woohyun; Chan Shin, Yong; Han, In W.; Byun, Yoonhyeong; Lee, Hae W.; Heo, Jin S.; Choi, Dong W.; Lim, Chang-Sup
• Is Part Of: HPB. Volume 23:Issue 10(2021)
• Page Start: 1623
• Page End: 1628
• Publication Date: 2021-10
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1016/j.hpb.2021.04.001
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Background: Intraductal papillary mucinous neoplasm (IPMN) is an broad-spectrum disease from benign to malignant. Inflammatory markers are known as prognostic predictors in various diseases. The purpose of this study was to determine the predictive value of inflammatory markers for prognosis in IPMN. Methods: From April 1995 to December 2016, patients who underwent pancreatectomy with pathologically confirmed IPMN at four tertiary centers were enrolled. Patients with a history of pancreatitis or cholangitis, and other malignancies were excluded. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and advanced lung cancer inflammation index (ALI) were calculated. Results: Of all, ninety-eight patients (26.8%) were diagnosed as invasive IPMN. The NLR and PLR were significantly elevated in invasive IPMN than in non-invasive disease (2.0 vs 1.8, p = 0.004; 117.1 vs 107.4, p = 0.009, respectively). ALI was significantly higher in non-invasive IPMN than in invasive disease (58.1 vs 45.9, p < 0.001). In multivariate analysis, only NLR showed significant association among the inflammatory markers studied ( p = 0.044). In invasive IPMN, the five-year recurrence-free survival rate for NLR less than 3.5 was superior to the rest (59.1 vs 42.2, p = 0.023). Conclusion: NLR may help to rightly select IPMN patients who will require surgery and may serve as a useful prognostic factor.